Other languages Delcath Systems, Inc.

Equities

DCTH

US24661P8077

Real-time Estimate Cboe BZX Other stock markets 13:59:23 2024-05-14 EDT			5-day change	1st Jan Change
7.15 ^USD	+32.41%		+25.39%	+72.12%

01:58pm	Stephens Starts Delcath Systems Wit Overweight Rating, $25 Price Target	MT
01:50pm	Earnings Flash (DCTH) DELCATH SYSTEMS Reports Q1 Revenue $3.1M, vs. Street Est of $2.2M	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Delcath Systems Says Phase 3 Data on Hepzato Kit Published in Oncology Journal	05-06
Delcath Systems, Inc Announces Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT	05-06
Delcath Systems Amends Supply, Manufacturing Agreement With Synerx Pharma, Mylan Teoranta for Melphalan Hydrochloride	04-26
Delcath Systems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26
Delcath Systems, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-26
Delcath Systems Names Chief Operating Officer	03-19
Delcath Systems, Inc. Appoints Martha S. Rook as Chief Operating Officer	03-18
Delcath Systems, Inc. Announces Healthcare Setting Locator for HEPZATO? KIT (melphalan/Hepatic Delivery System)	02-22
Delcath Systems, Inc. Announces Executive Changes	02-14
Delcath Systems Receives Permanent J-Code for HEPZATO? (melphalan/Hepatic Delivery System) Effective April 1, 2024	01-31
Delcath Systems Launches Hepzato Kit in US for Treatment of Metastatic Uveal Melanoma	01-16
Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing Hepzato Kit?	01-16
Delcath Systems Insider Bought Shares Worth $148,800, According to a Recent SEC Filing	11-20
Delcath Systems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13
Delcath Systems Secures $35 Million Funding Linked to FDA Approval of HEPZATO KIT; Shares Rise	23-09-01
Sentiment Subdued After Downbeat China Data, Pushing US Equity Futures Lower Pre-Bell	23-08-15
Top Premarket Gainers	23-08-15
Delcath Systems Says FDA Approved HEPZATO KIT for Metastatic Uveal Melanoma	23-08-15
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma	23-08-14
Delcath Systems, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Delcath Systems, Inc.

Equities

DCTH

US24661P8077

Other languages

Filters